Research Article

Applicability of High-Frequency Ultrasound to the Early Diagnosis of Diabetic Peripheral Neuropathy

Xishun Ma, Tongxia Li, Lizhen Du, Gang Liu, Ting Sun, and Tongliang Han

1Department of Ultrasound, Qingdao Municipal Hospital, Qingdao, Shandong 266071, China
2Department of Tuberculosis, Qingdao Chest Hospital, Qingdao Central Medical Group, Qingdao, Shandong 266043, China

Correspondence should be addressed to Lizhen Du; 78775272@qq.com and Tongliang Han; hantongliang_qd@sina.com

Received 6 February 2021; Revised 24 February 2021; Accepted 2 March 2021; Published 18 March 2021

Abstract

This study investigated the applicability of high-frequency ultrasound (HFU) to the early diagnosis of diabetic peripheral neuropathy (DPN). Patients with type 2 diabetes (N = 60) were divided into diabetic nonperipheral neuropathy and DPN groups (group A and group B, respectively; n = 30 each) based on electroneurophysiologic findings. Additionally, 30 nondiabetic patients were included as the healthy control group (group C). We calculated the cross-sectional area (CSA) of the median nerve (MN) of the right upper limb at 7 different sites (MN1–7) based on measured width (W) and thickness (T). Ultrasound imaging characteristics of the MN including internal echo, internal structure, boundary, epineurium, and blood flow were recorded. The 90 subjects (51 male and 39 female) had an average age of 56.09 ± 12.66 years. W, T, and CSA of the MN were increased in group A compared to group C (with significant differences at MN1, MN4, and MN7 (P < 0.05)) and in group B compared to group C (with significant differences at all 7 levels, especially MN6 and MN7 (P < 0.05)). Receiver operating characteristic curve analysis showed that CSA at the MN7 level had the highest diagnostic accuracy for DPN in group B, with a threshold value of 12.42 mm². Ultrasound examination revealed that the MN had lost the internal sieve mesh structure and showed reduced echo, a partial blood flow signal, and thickened epineurium in patients with DPN; these findings were particularly obvious at MN6 and MN7, corresponding to the carpal tunnel. CSA was positively correlated with motor latency and F wave average latency and negatively correlated with motor conduction velocity, motor amplitude, and sensory conduction velocity in group B. Thus, HFU may be useful for the early diagnosis of DPN, which can improve clinical outcomes.

1. Introduction

Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes. At present, the diagnosis of DPN mainly depends on electroneurophysiologic examination, but this has drawbacks such as invasiveness and high costs in terms of time and resources. The development of high-frequency ultrasound (HFU) has permitted the analysis of the morphologic features of peripheral nerves, thus enabling early detection of lesions. In the present study, we examined the applicability of HFU to the early diagnosis of DPN by retrospective analysis of data from patients with DPN and diabetic nonperipheral neuropathy (DNPN).

2. Materials and Methods

2.1. Participants. We analyzed data for 60 patients with type 2 diabetes who were admitted to the Endocrinology Department of Qingdao Municipal Hospital from October 2019 to October 2020 along with data for 30 healthy subjects collected during the same period. PASS software was used to calculate sample size. The ethics committee of the hospital approved the study, and informed consent was acquired from patients or families. The right upper limb median nerve was selected as the specific study object for the following reasons: no significant difference between unilateral and bilateral upper limbs and electrophysiological examination of the right upper limb. All patients met the 1999 World Health...
Organization diagnostic criteria for diabetes. Based on findings from the electroneurophysiologic examination, the patients were divided into DNPN and DPN groups (groups A and B, respectively); the 30 healthy subjects served as the control group (group C). Group A had 20 males and 10 females; group B had 19 males and 11 females; and group C had 12 males and 18 females. Patients with neuropathy caused by type 1 diabetes, lumbar spine disease, cerebrovascular disease, trauma, etc. were excluded. There were no statistically significant differences in age and sex ratios among the groups.

### 2.2. HFU Scan
The HFU linear array probe of a LOGIQ E8 (GE Healthcare, Little Chalfont, UK) or EPIQ 7 (Philips, Amsterdam, the Netherlands) ultrasound system was used for HFU scanning. The subject was in a supine position with right upper extremity abduction. The probe was placed vertically near the ulnar brachial artery of the subject’s right upper limb to locate the median nerve (MN), which was measured at 7 different sites including 4–5 cm above the elbow (MN1), at the elbow joint (MN2), at the pronator teres entrance level (MN3), 4–5 cm above the transverse wrist stripes (MN4), at the transverse wrist stripes (MN5), at the pea bone level (MN6), and at the hook bone level (MN7). Vertical and cross-sectional scanning was performed. The width (W) and thickness (T) of the MN were measured and used to calculate the cross-sectional area (CSA). Additionally, changes in internal structure, echo, blood flow, and the epineurium at the 7 sites were recorded.

### 2.3. Electroneurophysiologic Examination
For neuroelectrophysiologic recordings, the patient was relaxed and in a supine position under constant temperature and quiet conditions. The following motor and sensory nerve conduction and F wave parameters were measured: distal motor latency (DML), mixed nerve action potential, motor conduction velocity (MCV), sensory nerve action potential, sensory conduction velocity (SCV), and F-wave average latency (F-AL).

All operators were experienced doctors, and all measurements were obtained under double-blind test.

### 2.4. Statistical Analysis
Data are presented as mean ± standard deviation and were analyzed using SPSS v22.0 software (SPSS Inc., Chicago, IL, USA). Single-factor analysis of variance and the t-test were used to compare quantitative data, and the chi-squared test was used for categorical variables. Receiver operating characteristic (ROC) curve analysis was carried out to determine the optimal threshold value for accurate diagnosis of DPN. Correlation analysis was performed by linear regression. Differences with P < 0.05 were considered statistically significant.

### 3. Results

#### 3.1. Comparison of MN Ultrasound Measurements between Groups
The size of the MN in group C decreased from the proximal part to the distal end. W, T, and CSA of the MN were increased in group A compared to group C, with significant differences at MN1, MN4, and MN7 (P < 0.05). Similarly, W, T, and CSA of the MN were increased in group B compared to groups C and A, with significant differences at all 7 levels but especially at MN6 and MN7 (P < 0.05) (Tables 1 and 2).

#### 3.2. ROC Curve Analysis of CSA at Different Sites along the MN in DPN Patients
Patients with DPN had larger area under the ROC curve (AUC) for CSA of the MN than the other groups, with higher specificity and sensitivity at MN6 and MN7 than at other levels. MN6 and MN7 corresponded to the carpal tunnel. MN7 had the highest AUC at 0.88, with a specificity and specificity of 0.73 and 0.88, respectively; thus, the diagnostic accuracy was the highest at the MN7 level. The optimal threshold value of CSA was 12.42 mm² (Figure 1 and Table 3).

#### 3.3. HFU Features of the MN
The results of HFU scans showed that the MN in group C had a mesh-like structure in cross section, with a clear internal structure and boundary, uniform thickness of the epineurium, and parallel bands of high and low echoes in vertical sections (Figure 2). There was no obvious blood flow in the nerve. Compared to group C, in groups A and B, the internal sieve mesh structure of the MN was lost (group A, 76.7%; group B, 96.7%; and group C, 36.7%); moreover, the echo was reduced (group A, 66.7%; group B, 96.7%; group C, 36.7%) and there was a partial blood flow signal (group A, 26.7%; group B, 40%; and group C, 6.7%), accompanied by a thickened epineurium. These HFU findings were especially obvious at MN6 and MN7.

| MN level | Group A | Group B | Group C |
|----------|---------|---------|---------|
|          | W       | T       | CSA     | W       | T       | CSA     | W       | T       | CSA     |
| MN1      | 4.91 ± 0.70 | 2.93 ± 0.39 | 11.31 ± 2.33 | 5.00 ± 0.46 | 3.09 ± 0.51 | 12.19 ± 2.52 | 4.51 ± 0.49 | 2.80 ± 0.33 | 9.88 ± 1.33 |
| MN2      | 4.91 ± 0.65 | 2.71 ± 0.35 | 10.49 ± 1.98 | 5.26 ± 0.68 | 2.92 ± 0.48 | 11.99 ± 2.42 | 4.60 ± 0.57 | 2.68 ± 0.39 | 9.66 ± 1.72 |
| MN3      | 4.42 ± 0.69 | 2.23 ± 0.39 | 7.75 ± 1.92 | 4.81 ± 0.68 | 2.29 ± 0.44 | 8.66 ± 2.05 | 4.30 ± 0.65 | 2.08 ± 0.32 | 7.05 ± 1.63 |
| MN4      | 4.20 ± 0.57 | 2.61 ± 0.52 | 8.61 ± 2.03 | 4.38 ± 0.69 | 2.65 ± 0.37 | 9.11 ± 1.91 | 3.90 ± 0.54 | 2.40 ± 0.34 | 7.36 ± 1.59 |
| MN5      | 5.96 ± 1.02 | 2.21 ± 0.30 | 10.36 ± 2.33 | 6.44 ± 0.70 | 2.35 ± 0.31 | 11.91 ± 2.20 | 5.70 ± 0.64 | 2.11 ± 0.25 | 9.45 ± 1.76 |
| MN6      | 5.68 ± 0.75 | 2.33 ± 0.23 | 10.37 ± 1.64 | 6.64 ± 0.66 | 2.50 ± 0.30 | 13.09 ± 2.04 | 5.79 ± 0.72 | 2.11 ± 0.30 | 9.62 ± 1.96 |
| MN7      | 6.01 ± 0.76 | 2.47 ± 0.28 | 11.48 ± 1.71 | 6.77 ± 0.60 | 2.55 ± 0.25 | 13.57 ± 1.71 | 5.44 ± 0.90 | 2.08 ± 0.42 | 8.87 ± 2.28 |

CSA: cross-sectional area (mm²); MN: median nerve; T: thickness (mm); W: width (mm).
The MN in groups A and B showed significant reductions in the internal sieve mesh structure, echo, and blood flow compared to group C ($P < 0.05$); and between groups A and B, the differences in the decreased internal echo and loss of mesh structure were significant ($P < 0.05$), whereas blood flow signals were comparable ($P > 0.05$) (Table 4).

3.4. Correlation Analysis between HFU Measurements and Electroneurophysiologic Parameters in DPN Patients. The CSA of the MN in the DPN group was positively correlated with DML and F-AL and negatively correlated with MNAP, MCV, and SCV (Table 5).

### 4. Discussion

DPN is one of the most common chronic complications of diabetes, developing in more than half of patients [1]. The main clinical manifestations are symmetric pain, numbness, loss or disappearance of pain and temperature sensitivity, muscle weakness, and muscle atrophy of bilateral extremities as well as typical glove- and sock-like sensory disorders [2, 3]. DPN has an insidious onset and high incidence, and its pathologic severity is not proportional to clinical symptoms, as many patients are asymptomatic for a long time. It has been reported that 10% of newly diagnosed type 2 diabetes patients already have peripheral neuropathy when the disease course is >10 years [4], and more than 50% of patients develop varying degrees of DPN, which is associated with serious complications such as foot gangrene and ulcers that can seriously affect the quality of life of patients. Therefore, early diagnosis of DPN is critical to ensure a good clinical outcome.

The pathogenesis of DPN is unclear; because of the existence of many types of peripheral neuropathy, it is difficult to explain all of the pathologic features by a single mechanism. Long-term hyperglycemia metabolic disorder and

---

**Table 2: Comparisons of $W$, $T$, and CSA at different levels of the median nerve between groups ($t$-test).**

| MN level | $W$ | $T$ | CSA |
|----------|-----|-----|-----|
|          | $t$ statistic | $P$ | $t$ statistic | $P$ | $t$ statistic | $P$ |
| Group A vs. group C | | | | | | |
| MN1 | 2.53 | 0.010 | 1.41 | 0.170 | 2.93 | $\leq 0.001$ |
| MN2 | 1.99 | 0.050 | 0.32 | 0.750 | 1.73 | 0.080 |
| MN3 | 0.71 | 0.480 | 1.58 | 0.120 | 1.53 | 0.130 |
| MN4 | 2.13 | 0.030 | 1.84 | 0.070 | 2.65 | 0.010 |
| MN5 | 1.19 | 0.230 | 1.41 | 0.160 | 1.72 | 0.090 |
| MN6 | $-0.57$ | 0.570 | 3.17 | $\leq 0.001$ | 1.60 | 0.110 |
| MN7 | 2.65 | 0.010 | 4.14 | $\leq 0.001$ | 5.01 | $\leq 0.001$ |

**Table 3: Receiver operating characteristic curve analysis for the cross-sectional area at different levels of the median nerve in diabetic peripheral neuropathy patients.**

| MN level | AUC | Sensitivity | Specificity | Optimal threshold for CSA |
|----------|-----|-------------|-------------|--------------------------|
| MN1 | 0.69 | 0.53 | 0.80 | 12.05 |
| MN2 | 0.72 | 0.50 | 0.82 | 11.79 |
| MN3 | 0.70 | 0.67 | 0.67 | 7.85 |
| MN4 | 0.67 | 0.77 | 0.57 | 7.62 |
| MN5 | 0.75 | 0.90 | 0.57 | 9.86 |
| MN6 | 0.87 | 0.93 | 0.70 | 10.71 |
| MN7 | 0.88 | 0.73 | 0.88 | 12.42 |

AUC: area under the receiver operating characteristic curve; CSA: cross-sectional area (mm$^2$); MN: median nerve; $T$: thickness (mm); $W$: width (mm).
Microvascular disease are the major risk factors; others include changes in nerve growth factor level, peroxide- and free radical-induced damage, and abnormal metabolism of essential fatty acids [5].

At present, the diagnosis of DPN mainly relies on clinical manifestations and electroneurophysiologic findings. However, by the time the patient shows clinical symptoms, there are already obvious lesions in the peripheral nerves and early intervention is not possible. Electroneurophysiologic examination is the gold standard for DPN diagnosis, but it is time-consuming, laborious, costly, and invasive and is thus unsuitable for routine DPN screening [6]. With advances in ultrasound technology in recent years including probes with higher frequency and better resolution, it has become possible to visualize internal structures such as the epineurium, perineurium, and nerve bundles with a diameter of ≤0.5 mm as well as some small nerves and cutaneous nerves. Thus, HFU provides valuable morphologic information that can complement electrophysiologic data [7, 8].

In this study, we compared the features of the MN of the right upper limb in patients with DPN or DNPN and healthy control subjects, including changes in size, internal echo, structure, and blood flow. In healthy subjects, CSA and anteroposterior diameter of the MN were reduced compared to the elbow joint, especially at the level of the carpal tunnel; and the shape was also changed from round or oval to flat oval. The \( W, T, \) and CSA at the 7 measured sites along the MN were increased in DNPN and DPN patients compared to controls; the differences were statistically significant. The level of aldose reductase was shown to be elevated in DPN,
The median nerve and neurophysiologic parameters at MN7 in diabetic peripheral neuropathy patients.

The CSA of the MN showed positive and negative correlations with electroneurophysiologic parameters in patients with DPN, indicating that HFU can to some extent reveal changes in the functional properties of nerves. Moreover, it can clearly display the anatomic position of nerves and their relationship to adjacent structures as well as morphologic changes. Thus, HFU can aid in the early diagnosis of DPN by allowing lesions to be detected at an early stage, which can improve clinical outcomes.

Because the gold standard for diagnosing DPN is neurophysiological examination, our diagnosis of DPN may be not accurate enough because of small samples. Therefore, large simples are needed for further confirmation.

**Data Availability**

All data generated or used in this study can be found in the article.

**Conflicts of Interest**

The authors declare that there is no conflict of interest regarding the publication of this paper.

**Authors’ Contributions**

Xishun Ma and Tongxia Li are co-first authors. Lizhen Du and Tongliang Han are cocorrespondence authors.

**Acknowledgments**

The authors thank all study participants. This work was supported by grants from Qingdao Medical Research Guidance Plan of 2020 (no. WJZD018).

---

**Table 4: Analysis of ultrasonographic features at the MN7 level of the median nerve.**

|                  | Blood flow | Mesh structure | Internal echo |
|------------------|------------|----------------|---------------|
|                  | With       | Without        | Reduction     | No change    |
| **Group C vs. group A** |            |                |               |             |
| Group C          | 2          | 28             | 19            | 11           | 11           | 19           |
| Group A          | 8          | 22             | 7             | 23           | 20           | 10           |
| \(\chi^2\)       | 4.32       | 9.77           |               | 5.41         |
| \(P\)            | 0.040      | \(\leq0.001\)  |               | 0.020        |

| **Group C vs. group B** |            |                |               |             |
| Group C          | 2          | 28             | 19            | 11           | 11           | 19           |
| Group B          | 12         | 18             | 1             | 29           | 29           | 1            |
| \(\chi^2\)       | 9.32       | 24.30          |               | 24.30        |
| \(P\)            | \(\leq0.001\) | \(\leq0.001\) |               | 0.010        |

| **Group B vs. group A** |            |                |               |             |
| Group A          | 8          | 22             | 7             | 23           | 20           | 10           |
| Group B          | 12         | 18             | 1             | 29           | 29           | 1            |
| \(\chi^2\)       | 1.20       | 5.19           |               | 9.02         |
| \(P\)            | 0.210      | 0.030          | \(\leq0.001\) |

**Table 5: Correlation analysis between the cross-sectional area of the median nerve and neurophysiologic parameters at MN7 in diabetic peripheral neuropathy patients.**

|                  | DML | MNAP | MCV | F-AL | SNAP | SCV |
|------------------|-----|------|-----|------|------|-----|
| **R**            | 0.61| \(-0.78\) | \(-0.56\) | 0.51 | \(-0.17\) | \(-0.54\) |
| **P**            | \(\leq0.001\) | \(\leq0.001\) | \(\leq0.001\) | 0.380 | \(\leq0.001\) |

DML: distal motor latency; F-AL: F-wave average latency; MCV: motion conduction velocity; MNAP: mixed nerve action potential; SCV: sensory conduction velocity; SNAP: sensory nerve action potential.
References

[1] E. L. Feldman, K. A. Nave, T. S. Jensen, and D. Bennett, “New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain,” Neuron, vol. 93, no. 6, pp. 1296–1313, 2017.

[2] J. Cliff, A. L. Jorgensen, R. Lord et al., “The molecular genetics of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis,” Critical Reviews in Oncology/Hematology, vol. 120, pp. 127–140, 2017.

[3] P. Parasoglou, S. Rao, and J. M. Slade, “Declining skeletal muscle function in diabetic peripheral neuropathy,” Clinical Therapeutics, vol. 39, no. 6, pp. 1085–1103, 2017.

[4] S. Tesfaye and D. Selvarajah, “Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy,” Diabetes/Metabolism Research and Reviews, vol. 28, Supplement 1, pp. 8–14, 2012.

[5] A. Dejgaard, “Pathophysiology and treatment of diabetic neuropathy,” Diabetic Medicine, vol. 15, no. 2, pp. 97–112, 1998.

[6] H. Liu, W. Liu, and J. R. Li, “Evaluation of 4 methods for diagnosing diabetic peripheral neuropathy,” Guangdong Medicine, vol. 31, no. 24, pp. 3253–3255, 2010.

[7] E. Gallardo, Y. Noto, and N. G. Simon, “Ultrasound in the diagnosis of peripheral neuropathy: structure meets function in the neuromuscular clinic,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 86, no. 10, pp. 1066–1074, 2015.

[8] B. Kelle, M. Evran, T. Ballı, and F. Yavuz, “Diabetic peripheral neuropathy: correlation between nerve cross-sectional area on ultrasound and clinical features,” Journal of Back and Musculoskeletal Rehabilitation, vol. 29, no. 4, pp. 717–722, 2016.

[9] J. Zhang, S. Wu, and S. He, “Observation and comparative study of high-frequency ultrasound and pathology of diabetic peripheral nerves,” Chinese Journal of Clinicians, vol. 9, no. 4, pp. 607–611, 2015.

[10] M. Jack and D. Wright, “Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy,” Translational Research, vol. 159, no. 5, pp. 355–365, 2012.

[11] N. A. El Boghdady and G. A. Badr, “Evaluation of oxidative stress markers and vascular risk factors in patients with diabetic peripheral neuropathy,” Cell Biochemistry and Function, vol. 30, no. 4, pp. 328–334, 2012.